Therapeutical Class：Macrolides, inhibit protein synthesis by binding to 50S ribosomal subunits

Indication：Staphylococci, Streptococcu, Listeria, M. pneumoniae, Bacteroids. Leginoella pneumophila, Mycobacterium fortuitum, Chlamydia trachomatis, Campylobacter jejuni, Bordetella pertussis.

Administraton：PO:

Adults: 250-500 mg q6-12h, max of 4 g/day.

Gastrointestinal prokinetic: IV 200 mg initially followed by 250 mg orally tid. Children: 30-50 mg/kg/day in 2-4 divided doses, max of 2 g/day.

IV:

Adults:15-20 mg/kg/day in divided 4 doses or 500-1000 mg q6h, max of 4 g/day.

Legionnaire,s disease: 1-4 g/day.

Children: 15-50 mg/kg/day in divided 4 doses, max of 4 g/day.

Renal impairment: Ccr <20 ml/min, 50-75% of normal dose.

Adverse Effect：Gl distress, rare skin rash, hepatotoxicity, QT prolongation, hearing loss, diarrhea, anorexia.

Contraindication：Concurrent use of dronedarone, pimozide, terfenadine, astemizole, cisapride, ergotamine, dihydroergotamine.

Pregnancy Risk：B

Supply：Erymycin XE “Erymycin” Cap 250mg（毅力黴素膠囊 榮民）＜00197＞